INFLUENZA

Novel mRNA-lipid nanoparticle vaccine encoding four mpox virus surface proteins generates robust immune responses against orthopoxviruses

by

In a recent study posted to the bioRxiv* preprint server, researchers described a messenger ribonucleic acid (mRNA)-lipid nanoparticle mpox vaccine encoding four conserved mpox virus surface proteins which induced mpox virus-specific immunity and elicited heterologous protection when challenged with lethal vaccinia virus. Study: A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives … Read more

The biological properties of the SARS-CoV-2 E protein in the context of HIV-1

by

In a recent study published in Retrovirologyresearchers assessed the effectiveness of severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 envelope (E) proteins against human immunodeficiency virus (HIV)-1. Study: The envelope proteins from SARS-CoV-2 and SARS-CoV potently reduce the infectivity of human immunodeficiency virus type 1 (HIV-1). Image Credit: Corona Borealis Studio/Shutterstock Background Viroporins are ion … Read more

Dyadic Receives Regulatory Approval to Initiate Phase 1

by

JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today … Read more